Skip to main content

Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on clinical-stage biopharmaceutical company Tiziana Life Sciences Ltd (NASDAQ: TLSA). Tiziana has disclosed plans to file INDs (Investigational New Drug applications) aiming to expand the clinical indications of its lead product, intranasal foralumab, into mild-to-moderate Alzheimer’s Disease (AD) and long COVID-19.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/tiziana-life-sciences-expansion-into-new-clinical-indications-proactive-research-analyst-254277864

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  246.82
-10.55 (-4.10%)
AAPL  342.56
-6.65 (-1.90%)
AMD  424.39
-64.80 (-13.25%)
BAC  47.04
-1.53 (-3.15%)
GOOG  264.00
-7.02 (-2.59%)
META  560.84
-35.38 (-5.93%)
MSFT  484.52
-13.78 (-2.77%)
NVDA  125.53
-20.45 (-14.01%)
ORCL  101.19
-9.38 (-8.48%)
TSLA  345.82
-28.59 (-7.64%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.